Molecular classification and biomarkers of clinical outcome in breast ductal carcinoma in situ: Analysis of TBCRC 038 and RAHBT cohorts
Autor: | Siri H. Strand, Belén Rivero-Gutiérrez, Kathleen E. Houlahan, Jose A. Seoane, Lorraine M. King, Tyler Risom, Lunden A. Simpson, Sujay Vennam, Aziz Khan, Luis Cisneros, Timothy Hardman, Bryan Harmon, Fergus Couch, Kristalyn Gallagher, Mark Kilgore, Shi Wei, Angela DeMichele, Tari King, Priscilla F. McAuliffe, Julie Nangia, Joanna Lee, Jennifer Tseng, Anna Maria Storniolo, Alastair M. Thompson, Gaorav P. Gupta, Robyn Burns, Deborah J. Veis, Katherine DeSchryver, Chunfang Zhu, Magdalena Matusiak, Jason Wang, Shirley X. Zhu, Jen Tappenden, Daisy Yi Ding, Dadong Zhang, Jingqin Luo, Shu Jiang, Sushama Varma, Lauren Anderson, Cody Straub, Sucheta Srivastava, Christina Curtis, Rob Tibshirani, Robert Michael Angelo, Allison Hall, Kouros Owzar, Kornelia Polyak, Carlo Maley, Jeffrey R. Marks, Graham A. Colditz, E. Shelley Hwang, Robert B. West |
---|---|
Přispěvatelé: | Institut Català de la Salut, [Strand SH] Department of Pathology, Stanford University School of Medicine, Stanford, CA 94305, USA. Department of Molecular Medicine, Aarhus University Hospital, 8200 Aarhus N, Denmark. [Rivero-Gutiérrez B, Risom T] Department of Pathology, Stanford University School of Medicine, Stanford, CA 94305, USA. [Houlahan KE] Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA 94305, USA. [Seoane JA] Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA 94305, USA. Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. [King LM] Department of Surgery, Duke University School of Medicine, Durham, NC 27708, USA, Vall d'Hebron Barcelona Hospital Campus |
Jazyk: | angličtina |
Rok vydání: | 2022 |
Předmět: |
Cancer Research
whole genome sequencing neoplasias::neoplasias por localización::neoplasias de la mama [ENFERMEDADES] precancer multiplex immunohistochemistry RNA gene expression profiling Otros calificadores::Otros calificadores::/genética [Otros calificadores] Neoplasms::Neoplasms by Site::Breast Neoplasms [DISEASES] Marcadors tumorals factores biológicos::biomarcadores::marcadores tumorales [COMPUESTOS QUÍMICOS Y DROGAS] Oncology ductal carcinoma in situ Other subheadings::Other subheadings::/genetics [Other subheadings] tumor microenvironment Mama - Càncer - Aspectes genètics prognosis progression Biological Factors::Biomarkers::Biomarkers Tumor [CHEMICALS AND DRUGS] breast classifier |
Zdroj: | Scientia Strand, S H, Rivero-Gutiérrez, B, Houlahan, K E, Seoane, J A, King, L M, Risom, T, Simpson, L A, Vennam, S, Khan, A, Cisneros, L, Hardman, T, Harmon, B, Couch, F, Gallagher, K, Kilgore, M, Wei, S, DeMichele, A, King, T, McAuliffe, P F, Nangia, J, Lee, J, Tseng, J, Storniolo, A M, Thompson, A M, Gupta, G P, Burns, R, Veis, D J, DeSchryver, K, Zhu, C, Matusiak, M, Wang, J, Zhu, S X, Tappenden, J, Ding, D Y, Zhang, D, Luo, J, Jiang, S, Varma, S, Anderson, L, Straub, C, Srivastava, S, Curtis, C, Tibshirani, R, Angelo, R M, Hall, A, Owzar, K, Polyak, K, Maley, C, Marks, J R, Colditz, G A, Hwang, E S & West, R B 2022, ' Molecular classification and biomarkers of clinical outcome in breast ductal carcinoma in situ : Analysis of TBCRC 038 and RAHBT cohorts ', Cancer Cell, vol. 40, no. 12, pp. 1521-1536.e7 . https://doi.org/10.1016/j.ccell.2022.10.021 |
ISSN: | 5112-0011 |
Popis: | Ductal carcinoma in situ; Tumor microenvironment; Whole genome sequencing Carcinoma ductal in situ; Microambiente tumoral; Secuenciación del genoma completo Carcinoma ductal in situ; Microambient tumoral; Seqüenciació del genoma complet Ductal carcinoma in situ (DCIS) is the most common precursor of invasive breast cancer (IBC), with variable propensity for progression. We perform multiscale, integrated molecular profiling of DCIS with clinical outcomes by analyzing 774 DCIS samples from 542 patients with 7.3 years median follow-up from the Translational Breast Cancer Research Consortium 038 study and the Resource of Archival Breast Tissue cohorts. We identify 812 genes associated with ipsilateral recurrence within 5 years from treatment and develop a classifier that predicts DCIS or IBC recurrence in both cohorts. Pathways associated with recurrence include proliferation, immune response, and metabolism. Distinct stromal expression patterns and immune cell compositions are identified. Our multiscale approach employed in situ methods to generate a spatially resolved atlas of breast precancers, where complementary modalities can be directly compared and correlated with conventional pathology findings, disease states, and clinical outcome. This publication is part of the HTAN (Human Tumor Atlas Network) Consortium paper package. A list of HTAN members is available at humantumoratlas.org/htan-authors/. R01 CA185138-01 (E.S.H.); U2C CA-17-035 Pre-Cancer Atlas (PCA) Research Centers (E.S.H., R.B.W., C.M., K.P., G.A.C., K.O.); UO1 CA214183 (J.R.M.); DOD BC132057 (E.S.H., C.M.); BCRF 19-074 (E.S.H.); BCRF 19-028 (G.A.C.); PRECISION CRUK Grand Challenge (E.S.H.); R01CA193694 (R.B.W., G.A.C.), BCRF PPI-18-006 (R.B.W.). AEI RYC2019- 026576-I, "LaCaixa" Foundation LCF/PR/PR17/51120011 (J.A.S.). S.H.S. was supported by the Lundbeck Foundation (R288-2018-35) and the Danish Cancer Society (R229-A13616). K.E.H. was supported by a CIHR Banting Postdoctoral Fellowship. TBCRC 038 was conducted by the TBCRC, which receives major funding support from The Breast Cancer Research Foundation and Susan G. Komen. Some results in this paper are based upon data generated by the TCGA Research Network. |
Databáze: | OpenAIRE |
Externí odkaz: |